SIGHT SCIENCES INC. - COMMON STOCK

Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting

14 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital

23 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights

08 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors

28 Dec 2023 08:15:21 By Nasdaq GlobeNewswire

Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

18 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology

08 Dec 2023 07:05:00 By Nasdaq GlobeNewswire

Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023

07 Nov 2023 15:05:01 By Nasdaq GlobeNewswire

Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023

24 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023

19 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting

12 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

03 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023

11 Sep 2023 15:06:00 By Nasdaq GlobeNewswire

Sight Sciences Appoints Matt Link as Chief Commercial Officer

11 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference

30 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

03 Aug 2023 15:05:01 By Nasdaq GlobeNewswire

Sight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023

20 Jul 2023 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Technology to Restasis¹ for the Treatment of Dry Eye

20 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)

21 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Sight Sciences Announces Addition of New Director Catherine Mazzacco

09 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical System Technology

23 May 2023 07:30:01 By Nasdaq GlobeNewswire